Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$236.59 USD

236.59
602,304

+7.46 (3.26%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $237.00 +0.41 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

ESLOY vs. PODD: Which Stock Is the Better Value Option?

by Zacks Equity Research

ESLOY vs. PODD: Which Stock Is the Better Value Option?

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD) owing to strength in Omnipod 5 and its focus on market expansion.

Insulet (PODD) Launches the Omnipod 5 AID System in the UK

by Zacks Equity Research

Insulet (PODD) commercializes its revolutionary Omnipod 5 AID System in the United Kingdom.

ESLOY or PODD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ESLOY vs. PODD: Which Stock Is the Better Value Option?

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?

by Zacks Equity Research

Sector ETF report for RYH

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.

HAE or PODD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HAE vs. PODD: Which Stock Is the Better Value Option?

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Zacks.com featured highlights include Franklin Electric, Insulet and Wingstop

by Zacks Equity Research

Franklin Electric, Insulet and Wingstop are part of the Zacks Screen of the Week article.

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Tirthankar Chakraborty headshot

3 Top Stocks to Buy Now for Stellar Earnings Growth

by Tirthankar Chakraborty

Stocks such as Franklin Electric (FELE), Insulet (PODD) & Wingstop (WING) have striking earnings growth and positive estimate revisions.

Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay

by Zacks Equity Research

Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.

Zacks Industry Outlook Highlights Stryker, Boston Scientific, Zimmer Biomet and Insulet

by Zacks Equity Research

Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.

Here's Why Investors Should Retain Syneos Health (SYNH) for Now

by Zacks Equity Research

Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.

Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up

by Zacks Equity Research

Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.

Indrajit Bandyopadhyay headshot

4 Medical Products Stocks to Capitalize on the Industry's Recovery

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.

Insulet (PODD) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of 155.56% and 8.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Nalak Das headshot

Buy These 5 Stocks Ahead of Earnings Releases This Week

by Nalak Das

We have narrowed our search to five stocks that are set to report earnings results this week. These are: PODD, BKNG, BILL, JCI and COLD.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

National Vision's (EYE) share price is likely to grow following the company's efforts to expand remote capabilities and investments in doctor recruiting and retention efforts.

DraftKings (DKNG) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

DraftKings' (DKNG) first-quarter 2023 performance is likely to have benefited from the robust demand for mobile sports betting and expansion efforts in new states.

BellRing Brands (BRBR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

BellRing Brands (BRBR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alcon (ALC) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.